Fundamental Analysis of ERIS Lifesciences Ltd

About the Company - ERIS Lifesciences Ltd

Eris Lifesciences Ltd. is a Public Limited Listed company incorporated on 25/01/2007 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24232GJ2007PLC049867 and registration number is 049867. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1215.73 Cr. and Equity Capital is Rs. 13.59 Cr. for the Year ended 31/03/2022.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Ahmedabad Gujarat 380054	complianceofficer@erislifesciences.com http://www.eris.co.in

Management
Name	Position Held
Mr. Amit Bakshi	Chairperson & Managing Director
Mr. Krishnakumar Vaidyanathan	COO & Executive Director
Mr. Inderjeet Singh Negi	Executive Director
Mr. Kaushal Shah	Executive Director
Mr. Rajeev Dalal	Independent Director
Mr. Vasudevan Sujesh	Independent Director
Ms. Kalpana Unadkat	Independent Director
Mr. Prashant Gupta	Independent Director

Basic Stock Data of ERIS Lifesciences Ltd

Last Updated: July 6, 2024, 12:11 pm

Market Cap	13,770 Cr.
Current Price	1,012
High / Low	1,090/686
Stock P/E	35.1
Book Value	190
Dividend Yield	0.73 %
ROCE	11.3 %
ROE	16.4 %
Face Value	1.00
PEG Ratio	6.50

ERIS Lifesciences Ltd Quarterly Results

Month	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023
Sales	330	310	278	349	360	332	306	399	461	423	403	467	505
Expenses	205	203	184	223	220	210	209	269	309	286	284	297	324
Operating Profit	125	107	95	127	140	122	97	129	151	137	119	170	181
OPM %	38%	35%	34%	36%	39%	37%	32%	32%	33%	32%	30%	36%	36%
Other Income	2	3	2	6	7	5	8	3	5	2	1	1	3
Interest	0	0	1	1	1	1	1	7	7	3	9	17	16
Depreciation	11	11	11	15	15	17	18	23	29	30	35	41	42
Profit before tax	116	99	85	117	131	109	85	101	121	107	76	112	126
Tax %	7%	9%	19%	9%	9%	8%	6%	8%	1%	6%	19%	17%	3%
Net Profit	108	90	68	107	118	101	80	93	119	100	61	94	122
EPS in Rs	7.93	6.64	5.03	7.86	8.71	7.41	5.91	6.96	8.85	7.49	4.81	6.98	9.07

Last Updated: July 1, 2024, 5:30 pm

ERIS Lifesciences Ltd Quarterly Chart

ERIS Lifesciences Ltd Profit & Loss

Month	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Sales	274	393	509	546	597	750	856	982	1,074	1,212	1,347	1,685	1,861
Expenses	215	307	414	427	425	480	533	637	702	781	858	1,146	1,216
Operating Profit	59	86	95	118	172	269	322	345	372	431	489	539	645
OPM %	21%	22%	19%	22%	29%	36%	38%	35%	35%	36%	36%	32%	35%
Other Income	1	1	9	7	3	25	26	31	12	9	22	9	10
Interest	1	1	0	0	0	1	11	23	2	2	4	26	61
Depreciation	3	3	5	16	20	23	26	36	50	43	65	117	164
Profit before tax	55	83	98	109	154	270	312	317	331	394	442	405	430
Tax %	33%	30%	28%	18%	13%	9%	6%	8%	11%	10%	8%	8%
Net Profit	37	58	71	89	135	247	295	291	297	355	406	374	379
EPS in Rs	2,686.55	4,232.73	5,121.45	6,489.45	9,714.18	17.95	21.39	21.15	21.84	26.16	29.88	28.10	28.41
Dividend Payout %	0%	0%	0%	0%	63%	0%	0%	0%	13%	21%	20%	26%

ERIS Lifesciences Ltd Profit & Loss Yearly Chart

ERIS Lifesciences Ltd Growth

Compounded Sales Growth
10 Years:	15%
5 Years:	15%
3 Years:	18%
TTM:	19%

Compounded Profit Growth
10 Years:	19%
5 Years:	6%
3 Years:	4%
TTM:	6%

Stock Price CAGR
10 Years:	%
5 Years:	16%
3 Years:	11%
1 Year:	51%

Return on Equity
10 Years:	25%
5 Years:	21%
3 Years:	19%
Last Year:	16%

Last Updated: July 2, 2024, 5:01 pm

ERIS Lifesciences Ltd Balance Sheet

Month	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Sep 2023
Equity Capital	0	0	0	0	0	14	14	14	14	14	14	14	14
Reserves	48	106	176	266	299	553	848	1,137	1,283	1,563	1,895	2,182	2,398
Borrowings	5	3	1	1	0	1	377	176	0	7	84	877	830
Other Liabilities	49	63	94	91	98	124	170	175	205	202	233	337	634
Total Liabilities	102	172	271	357	397	692	1,408	1,502	1,502	1,785	2,226	3,410	3,875
Fixed Assets	23	27	75	72	71	232	771	761	875	854	918	2,568	2,520
CWIP	0	0	0	0	0	0	0	3	4	2	27	22	58
Investments	13	47	84	167	190	303	365	356	78	294	520	37	22
Other Assets	65	98	112	119	136	157	271	383	544	636	761	783	1,275
Total Assets	102	172	271	357	397	692	1,408	1,502	1,502	1,785	2,226	3,410	3,875

ERIS Lifesciences Ltd Reserves and Borrowings Chart

ERIS Lifesciences Ltd Cash Flow

Month	Mar 2012	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Cash from Operating Activity	30	38	90	90	131	200	235	223	271	375	378	292
Cash from Investing Activity	-19	-36	-83	-92	-44	-184	-590	-5	123	-323	-320	-975
Cash from Financing Activity	-10	-3	-2	0	-84	-24	363	-221	-335	-82	-45	688
Net Cash Flow	1	-1	5	-2	4	-8	8	-3	60	-30	14	5

ERIS Lifesciences Ltd Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	15	16	16	16	24	28	31	53	42	44	63	77
Inventory Days	214	166	223	178	195	178	196	148	145	166	136	182
Days Payable	109	138	142	92	134	247	200	213	157	166	129	258
Cash Conversion Cycle	120	43	97	102	84	-40	28	-12	30	44	70	0
Working Capital Days	31	7	15	9	23	-13	-17	59	64	76	92	83
ROCE %	98%	64%	47%	53%	60%	34%	26%	25%	27%	25%	17%

ERIS Lifesciences Ltd Financial Efficiency Indicators Chart

ERIS Lifesciences Ltd Share Holding Pattern

Month	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoters	52.69%	52.68%	52.66%	52.66%	52.30%	52.29%	52.70%	52.86%	52.86%	54.91%	54.90%	54.90%
FIIs	13.49%	13.60%	13.34%	13.31%	15.35%	15.39%	15.50%	14.86%	13.78%	13.20%	13.13%	14.27%
DIIs	10.05%	9.94%	10.37%	10.50%	10.66%	10.69%	9.95%	10.02%	10.73%	14.52%	14.55%	15.63%
Public	23.77%	23.78%	23.62%	23.52%	21.69%	21.63%	21.85%	22.27%	22.63%	17.37%	17.41%	15.20%
No. of Shareholders	46,477	49,833	54,223	57,061	51,639	48,055	46,746	45,931	44,169	42,245	46,496	51,753

ERIS Lifesciences Ltd Shareholding Pattern Chart

No. of ERIS Lifesciences Ltd Shareholders

ERIS Lifesciences Ltd Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
HDFC Small Cap Fund - Regular Plan	5,098,713	1.89	438.23	5,098,713	2024-07-05	0%
UTI Flexi Cap Fund	2,573,067	0.91	221.16	5,098,713	2024-07-05	-49.53%
Franklin India Smaller Companies Fund	1,710,900	1.52	147.05	5,098,713	2024-07-05	-66.44%
Aditya Birla Sun Life Equity Hybrid 95 Fund	1,368,030	1.7	117.58	5,098,713	2024-07-05	-73.17%
UTI Value Fund	1,029,126	1.19	88.45	5,098,713	2024-07-05	-79.82%
HSBC Midcap Fund	962,580	1.03	82.73	5,098,713	2024-07-05	-81.12%
HDFC Large and Mid Cap Fund - Regular Plan	675,000	0.49	58.02	5,098,713	2024-07-05	-86.76%
UTI Mid Cap Fund	591,612	0.58	50.85	5,098,713	2024-07-05	-88.4%
Tata ELSS Tax Saver Fund	512,000	1.27	44.01	5,098,713	2024-07-05	-89.96%
UTI Dividend Yield Fund	450,000	1.26	38.68	5,098,713	2024-07-05	-91.17%

ERIS Lifesciences Ltd ROCE Trend

ERIS Lifesciences Ltd EPS Trend

ERIS Lifesciences Ltd Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	1.00	1.00	1.00	1.00	1.00
Basic EPS (Rs.)	28.82	28.10	29.89	26.16	21.61
Diluted EPS (Rs.)	28.79	28.07	29.88	26.14	21.59
Cash EPS (Rs.)	42.61	36.12	34.61	29.32	25.54
Book Value[Excl.RevalReserv]/Share (Rs.)	236.86	163.30	140.35	116.10	95.47
Book Value[Incl.RevalReserv]/Share (Rs.)	236.86	163.30	140.35	116.10	95.47
Revenue From Operations / Share (Rs.)	147.70	123.92	99.10	89.25	79.10
PBDIT / Share (Rs.)	51.36	40.29	37.60	32.35	28.26
PBIT / Share (Rs.)	37.94	31.68	32.84	29.19	24.56
PBT / Share (Rs.)	31.70	29.76	32.53	29.05	24.40
Net Profit / Share (Rs.)	29.19	27.51	29.85	26.16	21.84
NP After MI And SOA / Share (Rs.)	28.82	28.10	29.88	26.16	21.84
PBDIT Margin (%)	34.77	32.51	37.93	36.24	35.73
PBIT Margin (%)	25.68	25.56	33.13	32.70	31.05
PBT Margin (%)	21.46	24.01	32.82	32.55	30.85
Net Profit Margin (%)	19.76	22.20	30.12	29.30	27.60
NP After MI And SOA Margin (%)	19.50	22.67	30.14	29.30	27.60
Return on Networth / Equity (%)	15.15	17.40	21.28	22.52	22.87
Return on Capital Employeed (%)	11.42	13.36	21.53	23.76	24.03
Return On Assets (%)	5.56	10.42	17.87	19.35	19.10
Long Term Debt / Equity (X)	0.25	0.29	0.02	0.00	0.00
Total Debt / Equity (X)	1.06	0.37	0.02	0.00	0.00
Asset Turnover Ratio (%)	0.37	0.52	0.61	0.67	0.67
Current Ratio (X)	0.90	1.73	3.14	2.80	2.91
Quick Ratio (X)	0.83	1.43	2.55	2.23	2.49
Inventory Turnover Ratio (X)	1.11	1.26	1.31	1.48	1.04
Dividend Payout Ratio (NP) (%)	0.00	26.15	20.10	21.02	13.14
Dividend Payout Ratio (CP) (%)	0.00	20.01	17.34	18.75	11.23
Earning Retention Ratio (%)	0.00	73.85	79.90	78.98	86.86
Cash Earning Retention Ratio (%)	0.00	79.99	82.66	81.25	88.77
Interest Coverage Ratio (X)	8.24	20.94	123.26	243.78	177.51
Interest Coverage Ratio (Post Tax) (X)	5.68	15.30	98.87	198.08	138.14
Enterprise Value (Cr.)	13413.39	8575.56	9359.51	8168.96	4936.17
EV / Net Operating Revenue (X)	6.68	5.09	6.95	6.74	4.60
EV / EBITDA (X)	19.20	15.65	18.31	18.60	12.86
MarketCap / Net Operating Revenue (X)	5.70	4.62	6.95	6.77	4.66
Retention Ratios (%)	0.00	73.84	79.89	78.97	86.85
Price / BV (X)	4.42	3.54	4.91	5.21	3.86
Price / Net Operating Revenue (X)	5.70	4.62	6.95	6.77	4.66
EarningsYield	0.03	0.04	0.04	0.04	0.05

ERIS Lifesciences Ltd Profitability Ratios (%)

ERIS Lifesciences Ltd Liquidity Ratios

ERIS Lifesciences Ltd Liquidity Ratios (%)

ERIS Lifesciences Ltd Interest Coverage Ratios (%)

ERIS Lifesciences Ltd Valuation Ratios

Fair Value

Fair Value: 1,101.70

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

Undervalued: 8.86% compared to the current price 1012

Intrinsic Value: 1,161.20

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators along with EPS growth.

Undervalued: 14.74% compared to the current price ₹1012

Last 5 Year EPS CAGR: 5.40%

*Investments are subject to market risks

Strength and Weakness of ERIS Lifesciences Ltd Stock

Strength	Weakness
The stock has a high average ROCE of 39.67%, which is a positive sign. The company has higher reserves (981.08 cr) compared to borrowings (181.69 cr), indicating strong financial stability. The company has shown consistent growth in sales (377.85 cr) and profit (261.54 cr) over the years.	The stock has a high average Working Capital Days of 35.75, which may not be favorable. The stock has a high average Cash Conversion Cycle of 47.17, which may not be favorable.

FAQ

What is the latest fair value of ERIS Lifesciences Ltd?

The latest fair value of ERIS Lifesciences Ltd is ₹1101.70.

What is the Market Cap of ERIS Lifesciences Ltd?

The Market Cap of ERIS Lifesciences Ltd is 13,770 Cr..

What is the current Stock Price of ERIS Lifesciences Ltd as on 06 July 2024?

The current stock price of ERIS Lifesciences Ltd as on 06 July 2024 is 1,012.

What is the High / Low of ERIS Lifesciences Ltd stocks in FY 2024?

In FY 2024, the High / Low of ERIS Lifesciences Ltd stocks is 1,090/686.

What is the Stock P/E of ERIS Lifesciences Ltd?

The Stock P/E of ERIS Lifesciences Ltd is 35.1.

What is the Book Value of ERIS Lifesciences Ltd?

The Book Value of ERIS Lifesciences Ltd is 190.

What is the Dividend Yield of ERIS Lifesciences Ltd?

The Dividend Yield of ERIS Lifesciences Ltd is 0.73 %.

What is the ROCE of ERIS Lifesciences Ltd?

The ROCE of ERIS Lifesciences Ltd is 11.3 %.

What is the ROE of ERIS Lifesciences Ltd?

The ROE of ERIS Lifesciences Ltd is 16.4 %.

What is the Face Value of ERIS Lifesciences Ltd?

The Face Value of ERIS Lifesciences Ltd is 1.00.